Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00655473 · ClinicalTrials.gov registry record · Phase 2

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

A Phase 2 study of Coronary Heart Disease, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
130
Enrollment target
12
Study locations

NCT00655473: Completed Phase 2 study of Coronary Heart Disease, sponsored by Hoffmann-La Roche.

NCT00655473 is a Phase 2 study of Coronary Heart Disease that has completed, run by Hoffmann-La Roche. The registered enrollment target is 130 participants, below the 1,481-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (91% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00655473, a Phase 2 study of Coronary Heart Disease, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
130 participants
Enrollment target
12
Study locations

Study Summary

This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors. After a pre-randomisation period during which positron emission tomography computed tomography (PET/CT) and MRI will be conducted, patients will be randomized to receive either RO4607381 600mg po daily, or placebo po daily. PET/CT and MRI scans will be taken at intervals during the study. The anticipated time on study treatment is 2 years, and the target sample size is 100 individuals.

Conditions Studied

Coronary Heart Disease

Interventions

  • DRUG Placebo
  • DRUG Dalcetrapib (RO4607381)

Study Locations (12)

Ohio

  • - Cincinnati
  • - Cincinnati
  • - Cleveland

Florida

  • - Jacksonville

Michigan

  • - Royal Oak

Minnesota

  • - Minneapolis

Missouri

  • - Kansas City

New York

  • - New York

North Carolina

  • - Statesville

Texas

  • - Houston

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2008-03
Est. Completion 2010-11
Phase Phase 2
Hoffmann-La Roche

909 total trials

What the finished NCT00655473 record still lists

NCT00655473 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,481-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Coronary Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00655473 lists 12 locations in 10 states (Ohio, Florida, Michigan).

Frequently Asked Questions

What is clinical trial NCT00655473 about?

NCT00655473 is a clinical study titled "A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease". This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors. After a pre-randomisation period during which positron emission tomography computed tomography (PET/CT) and MRI...

What is the current status of trial NCT00655473?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2008-03. Estimated completion is 2010-11.

What conditions does trial NCT00655473 study?

This clinical trial studies the following conditions: Coronary Heart Disease.

What interventions are being tested in trial NCT00655473?

The interventions under investigation include: Placebo (DRUG), Dalcetrapib (RO4607381) (DRUG).

Who is sponsoring clinical trial NCT00655473?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00655473 being conducted?

This trial has 12 study locations across Florida, Michigan, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00655473's enrollment target sits among peer trials

130 13th of 19 higher than 7 of 19 other Coronary Heart Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00655473, the US trial registry maintained by the National Library of Medicine. NCT00655473 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.